Predictors of outcome in children with Langerhans cell histiocytosis

被引:71
作者
Jubran, RF [1 ]
Marachelian, A [1 ]
Dorey, F [1 ]
Malogolowkin, M [1 ]
机构
[1] Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Div Pediat Hematol Oncol, Los Angeles, CA 90027 USA
关键词
children; histiocytosis; outcome;
D O I
10.1002/pbc.20364
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Our goal was to examine the clinical course of patients with Langerhans cell histiocytosis (LCH), with a special emphasis on bone disease and to attempt to identify and examine the factors that may predict reactivation and overall prognosis. Procedure. We conducted a retrospective chart review of 132 consecutive pediatric patients treated at Children's Hospital Los Angeles for LCH from 1984 to 2001. Results. The risk for reactivation after initial management is significantly higher for patients with multiple bone and those with Multiple organ involvement as compared with patients who had a single bone lesion (hazard ratios are 7.1 and 11.6). Patients Younger than 1 year in the multiple organ group have an increased risk of death at 2 years when compared with the older patients in that group (hazard ration=6.2, P=0.022). Endocrine abnormalities were seen in 20% and 7.5% of patients with or Without skull lesions respectively. Conclusions. Patients with LCH involving only the bones have a significantly better outcome than those with other organ involvement. Patients with multiple organ involvement who are less than 1 year of age are at high risk of death and should be approached more aggressively upfront. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:37 / 42
页数:6
相关论文
共 30 条
[1]   Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group [J].
Akkari, V ;
Donadieu, J ;
Piguet, C ;
Bordigoni, P ;
Michel, G ;
Blanche, S ;
Casanova, JL ;
Thomas, C ;
Vilmer, E ;
Fischer, A ;
Bertrand, Y .
BONE MARROW TRANSPLANTATION, 2003, 31 (12) :1097-1103
[2]   Clinical aspects of Langerhans cell histiocytosis [J].
Aricò, M ;
Egeler, RM .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1998, 12 (02) :247-+
[3]  
BROADBENT M, 1994, J CANC, V70, pS11
[4]   Current therapy for Langerhans cell histiocytosis [J].
Broadbent, V ;
Gadner, H .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1998, 12 (02) :327-+
[5]   Gastrointestinal involvement in disseminated langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine [J].
Choi, SW ;
Bangaru, BS ;
Wu, CD ;
Finlay, JL .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (06) :503-506
[6]  
CHU T, 1987, LANCET, V306, P208
[7]  
CLINE MJ, 1994, BLOOD, V84, P2840
[8]   Endocrine involvement in pediatric-onset Langerhans' cell histiocwosis: A population-based study [J].
Donadieu, J ;
Rolon, MA ;
Thomas, C ;
Burgieres, L ;
Plantaz, D ;
Emile, JF ;
Frappaz, D ;
David, M ;
Brauner, R ;
Genereau, T ;
Debray, D ;
Cabrol, S ;
Barthez, MA ;
Hoang-Xuan, K ;
Polak, M .
JOURNAL OF PEDIATRICS, 2004, 144 (03) :344-350
[9]   LANGERHANS CELL HISTIOCYTOSIS [J].
EGELER, RM ;
DANGIO, GJ .
JOURNAL OF PEDIATRICS, 1995, 127 (01) :1-11
[10]  
Ghanem S, 2003, J PEDIATR ORTHOPED, V23, P124